Sigilon Therapeutics is a clinical stage biotechnology company developing a class of therapeutics and functional cures for patients with chronic diseases. Co.'s product candidates include: SIG-005, which treats the non-neurological manifestations of mucopolysaccharidosis type 1 in patients with the disease; SIG-007, which provides continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; SIG-002, which is designed to replace islet cells for the treatment of Type 1 Diabetes; and SIG-001, which prevents bleeding episodes in patients with moderate to severe Hemophilia A. The SGTX stock yearly return is shown above.
The yearly return on the SGTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SGTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|